10-K Filing

CARGO THERAPEUTICS, INC. CIK: 1966494 FY 2024

Filing Information

Form Type	10-K
Accession Number	`0000950170-25-037929`
Period End Date	20241231
Filing Date	20250312
Fiscal Year	2024
Fiscal Period	FY
XBRL Instance	crgx-20241231_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 110 Income Statement 62 Cash Flow Statement 160 Stockholders Equity 48

Balance Sheet 110 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$64.38M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$64.38M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$405.73M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$405.73M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$275.32M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$275.32M	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$3.75M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$3.75M	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$5.31M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$5.31M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	500.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	500.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$409.48M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$409.48M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	500.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	500.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$345.01M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$345.01M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	500.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	500.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	41.21M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	41.21M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	46.04M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	46.04M	shares	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$28.39M	USD	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$28.39M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	41.21M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	41.21M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	46.04M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	46.04M	shares	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$28.22M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$28.22M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$23.48M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$23.48M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$10.38M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$10.38M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$11.29M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$11.29M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$5.31M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$5.31M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$4.39M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$4.39M	USD	Point-in-time
Total assets	`Assets`	$453.04M	USD	Point-in-time
Total assets	`Assets`	$453.04M	USD	Point-in-time
Total assets	`Assets`	$414.05M	USD	Point-in-time
Total assets	`Assets`	$414.05M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$5.01M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$5.01M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.44M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.44M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$7.24M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$7.24M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$12.52M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$12.52M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$9.44M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$9.44M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$6.63M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$6.63M	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$2.28M	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$2.28M	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$628.00K	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$628.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$25.03M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$25.03M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$21.16M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$21.16M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$28.80M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$28.80M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$26.26M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$26.26M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$225.00K	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$225.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$53.83M	USD	Point-in-time
Total liabilities	`Liabilities`	$53.83M	USD	Point-in-time
Total liabilities	`Liabilities`	$47.65M	USD	Point-in-time
Total liabilities	`Liabilities`	$47.65M	USD	Point-in-time
Common stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2024 and 2023; 46,042,504 and 41,205,551 shares issued and outstanding at December 31, 2024 and 2023, respectively	`CommonStockValue`	$41.00K	USD	Point-in-time
Common stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2024 and 2023; 46,042,504 and 41,205,551 shares issued and outstanding at December 31, 2024 and 2023, respectively	`CommonStockValue`	$41.00K	USD	Point-in-time
Common stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2024 and 2023; 46,042,504 and 41,205,551 shares issued and outstanding at December 31, 2024 and 2023, respectively	`CommonStockValue`	$46.00K	USD	Point-in-time
Common stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2024 and 2023; 46,042,504 and 41,205,551 shares issued and outstanding at December 31, 2024 and 2023, respectively	`CommonStockValue`	$46.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$550.49M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$550.49M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$672.54M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$672.54M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$291.00K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$291.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-145.15M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-145.15M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-312.65M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-312.65M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$405.39M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$405.39M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$360.23M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$360.23M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$453.04M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$453.04M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$414.05M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$414.05M	USD	Point-in-time

Income Statement 62 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$143.40M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$143.40M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$75.79M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$75.79M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$20.92M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$20.92M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$43.97M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$43.97M	USD	Annual
Total operating expenses	`OperatingExpenses`	$187.37M	USD	Annual
Total operating expenses	`OperatingExpenses`	$187.37M	USD	Annual
Total operating expenses	`OperatingExpenses`	$96.71M	USD	Annual
Total operating expenses	`OperatingExpenses`	$96.71M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-187.37M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-187.37M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-96.71M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-96.71M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$20.06M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$20.06M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$4.87M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$4.87M	USD	Annual
Interest expense	`InterestExpense`	-	USD	Annual
Interest expense	`InterestExpense`	-	USD	Annual
Interest expense	`InterestExpense`	$1.60M	USD	Annual
Interest expense	`InterestExpense`	$1.60M	USD	Annual
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$8.78M	USD	Annual
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$8.78M	USD	Annual
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	-	USD	Annual
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	-	USD	Annual
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$6.45M	USD	Annual
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$6.45M	USD	Annual
Loss on extinguishment of convertible notes	`GainsLossesOnExtinguishmentOfDebt`	$-2.32M	USD	Annual
Loss on extinguishment of convertible notes	`GainsLossesOnExtinguishmentOfDebt`	$-2.32M	USD	Annual
Other expense, net	`OtherNonoperatingIncomeExpense`	$-58.00K	USD	Annual
Other expense, net	`OtherNonoperatingIncomeExpense`	$-58.00K	USD	Annual
Other expense, net	`OtherNonoperatingIncomeExpense`	$-195.00K	USD	Annual
Other expense, net	`OtherNonoperatingIncomeExpense`	$-195.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-98.15M	USD	Annual
Net loss	`NetIncomeLoss`	$-98.15M	USD	Annual
Net loss	`NetIncomeLoss`	$-167.50M	USD	Annual
Net loss	`NetIncomeLoss`	$-167.50M	USD	Annual
Unrealized gain on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$291.00K	USD	Annual
Unrealized gain on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$291.00K	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-167.21M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-167.21M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-98.15M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-98.15M	USD	Annual
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-16.53	USD	Annual
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-16.53	USD	Annual
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-3.72	USD	Annual
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-3.72	USD	Annual
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-3.72	USD	Annual
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-3.72	USD	Annual
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-16.53	USD	Annual
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-16.53	USD	Annual
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	5.94M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	5.94M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	44.97M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	44.97M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	5.94M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	5.94M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	44.97M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	44.97M	shares	Annual

Cash Flow Statement 160 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-98.15M	USD	Annual
Net loss	`NetIncomeLoss`	$-98.15M	USD	Annual
Net loss	`NetIncomeLoss`	$-167.50M	USD	Annual
Net loss	`NetIncomeLoss`	$-167.50M	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$3.33M	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$3.33M	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$17.97M	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$17.97M	USD	Annual
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$4.42M	USD	Annual
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$4.42M	USD	Annual
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$2.20M	USD	Annual
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$2.20M	USD	Annual
Depreciation	`Depreciation`	$2.66M	USD	Annual
Depreciation	`Depreciation`	$2.66M	USD	Annual
Depreciation	`Depreciation`	$1.49M	USD	Annual
Depreciation	`Depreciation`	$1.49M	USD	Annual
Loss from disposal of property and equipment	`GainLossOnDispositionOfAssets1`	$-156.00K	USD	Annual
Loss from disposal of property and equipment	`GainLossOnDispositionOfAssets1`	$-156.00K	USD	Annual
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$1.50M	USD	Annual
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$1.50M	USD	Annual
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$300.00K	USD	Annual
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$300.00K	USD	Annual
Accretion on investments in marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$3.52M	USD	Annual
Accretion on investments in marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$3.52M	USD	Annual
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	-	USD	Annual
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	-	USD	Annual
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$6.45M	USD	Annual
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$6.45M	USD	Annual
Loss on extinguishment of convertible notes	`GainsLossesOnExtinguishmentOfDebt`	$-2.32M	USD	Annual
Loss on extinguishment of convertible notes	`GainsLossesOnExtinguishmentOfDebt`	$-2.32M	USD	Annual
Noncash interest expense	`PaidInKindInterest`	$1.60M	USD	Annual
Noncash interest expense	`PaidInKindInterest`	$1.60M	USD	Annual
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$8.78M	USD	Annual
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$8.78M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.59M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.59M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.66M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.66M	USD	Annual
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$375.00K	USD	Annual
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$375.00K	USD	Annual
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$3.61M	USD	Annual
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$3.61M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$757.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$757.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-2.10M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-2.10M	USD	Annual
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$4.67M	USD	Annual
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$4.67M	USD	Annual
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$5.80M	USD	Annual
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$5.80M	USD	Annual
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$2.90M	USD	Annual
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$2.90M	USD	Annual
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$3.79M	USD	Annual
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$3.79M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$1.21M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$1.21M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-1.81M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-1.81M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-81.16M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-81.16M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-139.74M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-139.74M	USD	Annual
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$604.87M	USD	Annual
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$604.87M	USD	Annual
Proceeds from sales and maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$304.97M	USD	Annual
Proceeds from sales and maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$304.97M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$4.45M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$4.45M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$8.28M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$8.28M	USD	Annual
Proceeds from sale of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$223.00K	USD	Annual
Proceeds from sale of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$223.00K	USD	Annual
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$950.00K	USD	Annual
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$950.00K	USD	Annual
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$715.00K	USD	Annual
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$715.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-305.08M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-305.08M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-8.99M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-8.99M	USD	Annual
Proceeds from issuance of common stock on initial public offering, net of commissions	`ProceedsFromIssuanceInitialPublicOffering`	$296.61M	USD	Annual
Proceeds from issuance of common stock on initial public offering, net of commissions	`ProceedsFromIssuanceInitialPublicOffering`	$296.61M	USD	Annual
Proceeds from issuance of common stock in private placement, net of issuance costs	`ProceedsFromIssuanceOfPrivatePlacement`	$102.89M	USD	Annual
Proceeds from issuance of common stock in private placement, net of issuance costs	`ProceedsFromIssuanceOfPrivatePlacement`	$102.89M	USD	Annual
Proceeds from issuance of convertible notes, net of issuance costs - related party	`ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCostsFromRelatedParty`	$2.21M	USD	Annual
Proceeds from issuance of convertible notes, net of issuance costs - related party	`ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCostsFromRelatedParty`	$2.21M	USD	Annual
Proceeds from issuance of convertible notes, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$1.29M	USD	Annual
Proceeds from issuance of convertible notes, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$1.29M	USD	Annual
Proceeds from issuance of redeemable convertible preferred stock and tranche obligations, net of issuance costs	`ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndTrancheObligationsNetOfIssuanceCosts`	$199.92M	USD	Annual
Proceeds from issuance of redeemable convertible preferred stock and tranche obligations, net of issuance costs	`ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndTrancheObligationsNetOfIssuanceCosts`	$199.92M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$1.17M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$1.17M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$34.00K	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$34.00K	USD	Annual
Payment of deferred initial public offering costs	`PaymentsOfStockIssuanceCosts`	$105.00K	USD	Annual
Payment of deferred initial public offering costs	`PaymentsOfStockIssuanceCosts`	$105.00K	USD	Annual
Payment of deferred initial public offering costs	`PaymentsOfStockIssuanceCosts`	$5.47M	USD	Annual
Payment of deferred initial public offering costs	`PaymentsOfStockIssuanceCosts`	$5.47M	USD	Annual
Payment of "at-the-market" equity offering program costs	`PaymentOfAtTheMarketEquityOfferingProgramCosts`	$463.00K	USD	Annual
Payment of "at-the-market" equity offering program costs	`PaymentOfAtTheMarketEquityOfferingProgramCosts`	$463.00K	USD	Annual
Payment of transaction costs for exchange of common stock for warrants	`PaymentOfTransactionCostsForExchangeOfCommonStockForWarrants`	$25.00K	USD	Annual
Payment of transaction costs for exchange of common stock for warrants	`PaymentOfTransactionCostsForExchangeOfCommonStockForWarrants`	$25.00K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$494.58M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$494.58M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$103.47M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$103.47M	USD	Annual
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-341.35M	USD	Annual
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-341.35M	USD	Annual
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$404.43M	USD	Annual
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$404.43M	USD	Annual
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$64.95M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$64.95M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$64.95M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$64.95M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$64.38M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$64.38M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$405.73M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$405.73M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$64.95M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$64.95M	USD	Point-in-time
Reclassification of tranche obligation asset to Series A-1 redeemable convertible preferred stock	`ReclassificationOfTrancheObligationAssetToSeriesA1RedeemableConvertiblePreferredStock`	$1.91M	USD	Annual
Reclassification of tranche obligation asset to Series A-1 redeemable convertible preferred stock	`ReclassificationOfTrancheObligationAssetToSeriesA1RedeemableConvertiblePreferredStock`	$1.91M	USD	Annual
Reclassification of tranche obligation liability to Series A-1 redeemable convertible preferred stock	`ReclassificationOfTrancheObligationLiabilityToSeriesA1RedeemableConvertiblePreferredStock`	$18.01M	USD	Annual
Reclassification of tranche obligation liability to Series A-1 redeemable convertible preferred stock	`ReclassificationOfTrancheObligationLiabilityToSeriesA1RedeemableConvertiblePreferredStock`	$18.01M	USD	Annual
Conversion of redeemable convertible preferred stock into common stock on completion of initial public offering	`ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockOnCompletionOfInitialPublicOffering`	$254.11M	USD	Annual
Conversion of redeemable convertible preferred stock into common stock on completion of initial public offering	`ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockOnCompletionOfInitialPublicOffering`	$254.11M	USD	Annual
Exchange of common stock for pre-funded warrants	`ExchangeOfCommonStockForPrefundedWarrants`	$37.60M	USD	Annual
Exchange of common stock for pre-funded warrants	`ExchangeOfCommonStockForPrefundedWarrants`	$37.60M	USD	Annual
Conversion of convertible notes to shares of Series A-2 redeemable convertible preferred stock	`ConversionOfConvertibleNotesToSharesOfSeriesA2RedeemableConvertiblePreferredStock`	$35.58M	USD	Annual
Conversion of convertible notes to shares of Series A-2 redeemable convertible preferred stock	`ConversionOfConvertibleNotesToSharesOfSeriesA2RedeemableConvertiblePreferredStock`	$35.58M	USD	Annual
Reclassification of shares of Series Seed redeemable convertible preferred stock to mezzanine equity	`ReclassificationOfSharesOfSeriesSeedRedeemableConvertiblePreferredStockToMezzanineEquity`	$9.83M	USD	Annual
Reclassification of shares of Series Seed redeemable convertible preferred stock to mezzanine equity	`ReclassificationOfSharesOfSeriesSeedRedeemableConvertiblePreferredStockToMezzanineEquity`	$9.83M	USD	Annual
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$388.00K	USD	Annual
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$388.00K	USD	Annual
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$883.00K	USD	Annual
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$883.00K	USD	Annual
In-process research and development costs in accounts payable, accrued clinical and research and development expenses, and other non-current liabilities	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$1.27M	USD	Annual
In-process research and development costs in accounts payable, accrued clinical and research and development expenses, and other non-current liabilities	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$1.27M	USD	Annual
In-process research and development costs in accounts payable, accrued clinical and research and development expenses, and other non-current liabilities	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$523.00K	USD	Annual
In-process research and development costs in accounts payable, accrued clinical and research and development expenses, and other non-current liabilities	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$523.00K	USD	Annual
Deferred offering costs related to initial public offering included in accounts payable, accrued expenses and other current liabilities	`DeferredOfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities`	$105.00K	USD	Annual
Deferred offering costs related to initial public offering included in accounts payable, accrued expenses and other current liabilities	`DeferredOfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities`	$105.00K	USD	Annual
Deferred issuance costs related to the "at-the-market" equity offering program, included in accrued expenses and other current liabilities	`DeferredIssuanceCostsRelatedToTheAtTheMarketEquityOfferingProgramIncludedInAccruedExpensesAndOtherCurrentLiabilities`	$82.00K	USD	Annual
Deferred issuance costs related to the "at-the-market" equity offering program, included in accrued expenses and other current liabilities	`DeferredIssuanceCostsRelatedToTheAtTheMarketEquityOfferingProgramIncludedInAccruedExpensesAndOtherCurrentLiabilities`	$82.00K	USD	Annual

Stockholders Equity 48 line items

Line Item	Tag	Value	Unit	Period
Commissions and offering costs	`CommissionsAndOfferingCosts`	$5.58M	USD	Annual
Commissions and offering costs	`CommissionsAndOfferingCosts`	$5.58M	USD	Annual
Beginning balance, shares	`TemporaryEquitySharesOutstanding`	0.00	shares	Point-in-time
Beginning balance, shares	`TemporaryEquitySharesOutstanding`	0.00	shares	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$360.23M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$360.23M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Exchange of common stock for pre-funded warrants, value	`ExchangeOfCommonStockForPrefundedWarrantsValue`	$25.00K	USD	Annual
Exchange of common stock for pre-funded warrants, value	`ExchangeOfCommonStockForPrefundedWarrantsValue`	$25.00K	USD	Annual
Issuance of common stock, net of issuance costs, commissions and offering costs, shares	`StockIssuedDuringPeriodSharesNewIssues`	18.75M	shares	Point-in-time
Issuance of common stock, net of issuance costs, commissions and offering costs, shares	`StockIssuedDuringPeriodSharesNewIssues`	18.75M	shares	Point-in-time
Exercise of stock options, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	208,452.00	shares	Annual
Exercise of stock options, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	208,452.00	shares	Annual
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$34.00K	USD	Annual
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$34.00K	USD	Annual
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.17M	USD	Annual
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.17M	USD	Annual
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$45.00K	USD	Annual
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$45.00K	USD	Annual
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$103.00K	USD	Annual
Vesting of restricted stock	`VestingOfRestrictedStockAwardValue`	$103.00K	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$17.97M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$17.97M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$3.33M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$3.33M	USD	Annual
Net loss	`NetIncomeLoss`	$-98.15M	USD	Annual
Net loss	`NetIncomeLoss`	$-98.15M	USD	Annual
Net loss	`NetIncomeLoss`	$-167.50M	USD	Annual
Net loss	`NetIncomeLoss`	$-167.50M	USD	Annual
Other comprehensive income	`OtherComprehensiveIncomeLossNetOfTax`	$291.00K	USD	Annual
Other comprehensive income	`OtherComprehensiveIncomeLossNetOfTax`	$291.00K	USD	Annual
Reclassification of series seed redeemable convertible preferred stock, amount	`ReclassificationOfSeriesSeedRedeemableConvertiblePreferredStockValue`	$-9.83M	USD	Annual
Reclassification of series seed redeemable convertible preferred stock, amount	`ReclassificationOfSeriesSeedRedeemableConvertiblePreferredStockValue`	$-9.83M	USD	Annual
Conversion of redeemable convertible preferred stock to common stock on initial public offering	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$254.11M	USD	Annual
Conversion of redeemable convertible preferred stock to common stock on initial public offering	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$254.11M	USD	Annual
Conversion of redeemable convertible preferred stock to common stock on initial public offering, Shares	`StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities`	18.84M	shares	Point-in-time
Conversion of redeemable convertible preferred stock to common stock on initial public offering, Shares	`StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities`	18.84M	shares	Point-in-time
Ending balance, shares	`TemporaryEquitySharesOutstanding`	0.00	shares	Point-in-time
Ending balance, shares	`TemporaryEquitySharesOutstanding`	0.00	shares	Point-in-time
Ending balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$360.23M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$360.23M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-35.24M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.